This episode of TWiV is focused on COVID-19 vaccines and antibodies: who should get boosters, whether a variant matched mRNA vaccine is superior to a historical vaccine, and how the interval between vaccination and infection influences the quality of the antibody response.

In COVID-19 clinical update #110, Dr. Griffin covers hospital admissions during variant outbreaks, viral load in vaccinated and unvaccinated individuals, predictive capacity of symptoms in children, comparison of antigen tests, incidence of myocarditis after vaccination, steroids during replication phase, Paxlovid efficacy and safety, fluvoxamine, sabizabutin, colchicine, and prevalence of infection in Africa.

In COVID-19 clinical update #109, Daniel Griffin discusses cardiac complications after infection or vaccination, long COVID in children, fourth vaccine dose in Israel, no need for fourth vaccine dose in EU, dexamethasone dosing, immunomodulation therapy, MIS outcomes in children, US long COVID effort launched, and herd immunity.

In COVID-19 clinical update #107, Daniel Griffin reviews vaccine booster doses, at-home testing, transmission in ferrets, improving indoor air quality, trials of BCG, ivermectin, and fluvoxamine, vaccination during pregnancy, mRNA vaccines and Fc functions, anti-platelet and aspirin therapy and a trial of prone positioning.

In COVID-19 clinical update #107, Daniel Griffin discusses Moderna vaccine results in children, hospitalization by ethnicity, BA.2 severity in children, placentitis and thrombohematoma during pregnancy, predictive value of symptoms for diagnosis, Evusheld activity against BA.1 and BA.2, Remdesivir resistance, Ivermectin with and without strongyloidiasis, inhaled ciclesonide, home telemonitoring, pulse oximetry for remote monitoring, effectiveness of anti-platelet therapy, and deaths in Zambia.

In COVID-19 clinical update #106, Daniel Griffin covers failure of ivermectin to improve hospitalization, increased hospitalization of children with Omicron, seroconversion of children versus adults, effectiveness of Pfizer mRNA vaccine in children, high vaccine effectiveness in Finland against Omicron, distinct long COVID clinical phenotypes, and estimating worldwide excess mortality.

In COVID-19 clinical update #104, Daniel Griffin reviews effectiveness of mRNA vaccines among children, number of children affected by disease, accuracy of rapid antigen tests, CDC guidance for prevention strategies, monoclonal antibody effectiveness, predicting progression to severe respiratory failure from pneumonia, risk of long COVID after two vaccine doses, and peripheral neuropathy in long COVID.

In COVID-19 clinical update #103, Daniel Griffin covers immunocompromised people, hospitalization of children, vaccine usage update, Omicron and cross-reactive neutralizing antibodies, reinfection prevents disease in hamsters, repeated infections with endemic coronaviruses, global burden of antimicrobial resistance, ivermectin not protective in hamsters, and Omicron evades therapeutic monoclonals.

In COVID-19 clinical update #102, Daniel Griffin reviews children and COVID, effectiveness of maternal vaccination, vaccines for immunocompromised, primary care physicians and vaccination rates, booster safety among adults, placentitis, azithromycin, oral Nirmatrelvir, Omicron antibody evasion, EUA for bebtelovimab, IL-1 blocking agents, thromboprophylaxis, effectiveness of vaccines against long COVID, and risks of mental health outcomes.